A genomic approach to predict synergistic combinations for breast cancer treatment
We leverage genomic and biochemical data to identify synergistic drug regimens for breast cancer. In order to study the mechanism of the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) in breast cancer, we generated and validated genomic profiles...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450767/ |